Form 13-F position report

RECURSION PHARMACEUTICALS IN

Reported by MORGAN STANLEY

RXRX CUSIP 75629V104 Manager CIK 0000895421

Reported 6,224,755 shares, up 3,481,256 (126.9%) from the prior quarter.

Reported value 155.3%; share count 126.9% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 6,224,755 Quarter-end amount reported
Reported value $25,708,241 Fair value at quarter end
Consecutive quarters held 22 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 1977000
2022-03-31 1005000
2022-06-30 1803000
2022-09-30 2937000
2022-12-31 2568748
2023-03-31 1729978
2023-06-30 2915011
2023-09-30 6170658
2023-12-31 25398364
2024-03-31 19578862
2024-06-30 13262352
2024-09-30 12370764
2024-12-31 19337168
2025-03-31 26505195
2025-06-30 28789445
2025-09-30 35576930
2025-12-31 23139501
2026-03-31 6708961
2026-06-30 10068644
2026-09-30 25708241

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for RECURSION PHARMACEUTICALS IN held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 6,224,755 +3,481,256 (126.9%) < 0.01% $25,708,241 2026-11-13
Q2 2026 Added 2,743,499 +558,170 (25.5%) < 0.01% $10,068,644 2026-08-13
Q1 2026 Reduced 2,185,329 -3,472,249 (-61.4%) < 0.01% $6,708,961 2026-05-15
Q4 2025 Reduced 5,657,578 -1,632,775 (-22.4%) < 0.01% $23,139,501 2026-02-13
Q3 2025 Added 7,290,353 +1,600,741 (28.1%) < 0.01% $35,576,930 2025-11-14
Q2 2025 Added 5,689,612 +679,179 (13.6%) < 0.01% $28,789,445 2025-08-15
Q1 2025 Added 5,010,433 +2,149,906 (75.2%) < 0.01% $26,505,195 2025-05-15
Q4 2024 Added 2,860,527 +983,326 (52.4%) < 0.01% $19,337,168 2025-02-14
Q3 2024 Added 1,877,201 +108,889 (6.2%) < 0.01% $12,370,764 2024-11-14
Q2 2024 Reduced 1,768,312 -195,465 (-10.0%) < 0.01% $13,262,352 2024-08-14
Q1 2024 Reduced 1,963,777 -612,122 (-23.8%) < 0.01% $19,578,862 2024-05-15
Q4 2023 Added 2,575,899 +1,769,277 (219.3%) < 0.01% $25,398,364 2024-02-13
Q3 2023 Added 806,622 +416,393 (106.7%) < 0.01% $6,170,658 2023-11-15
Q2 2023 Added 390,229 +130,862 (50.5%) < 0.01% $2,915,011 2023-08-14
Q1 2023 Reduced 259,367 -73,804 (-22.2%) < 0.01% $1,729,978 2023-05-15
Q4 2022 Added 333,171 +57,229 (20.7%) < 0.01% $2,568,748 2023-02-14
Q3 2022 Added 275,942 +54,424 (24.6%) < 0.01% $2,937,000 2022-11-14
Q2 2022 Added 221,518 +81,107 (57.8%) < 0.01% $1,803,000 2022-08-15
Q1 2022 Added 140,411 +24,996 (21.7%) < 0.01% $1,005,000 2022-05-13
Q4 2021 Added 115,415 +105,715 (1089.8%) < 0.01% $1,977,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

382 managers reported RECURSION PHARMACEUTICALS IN for Q3 2026.

Managers reporting RECURSION PHARMACEUTICALS IN in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 53,478,879 +3,174,188 < 0.01% $220,867,771 9 qtrs
ARK Investment Management LLC Added 44,745,025 +3,407,393 1.06% $184,796,952 22 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 35,812,145 +4,680,546 < 0.01% $147,904,159 3 qtrs
STATE STREET CORPORATION Reduced 30,001,137 -4,704,993 < 0.01% $123,904,696 22 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 23,004,367 +238,427 < 0.01% $95,008,036 3 qtrs
BAILLIE GIFFORD & CO Reduced 18,174,384 -5,313,523 0.07% $75,060,206 22 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 13,913,841 +94,706 < 0.01% $57,473,770 22 qtrs
SOFTBANK GROUP CORP Unchanged 13,636,515 0 0.35% $56,318,807 8 qtrs
FMR LLC Added 11,439,657 +11,393,301 < 0.01% $47,245,782 22 qtrs
UBS Group AG Reduced 8,430,018 -517,084 < 0.01% $34,815,974 22 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
CL A

Voting authority reported

Sole
4,492,362
Shared
0
None
1,732,393

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.